Rhodes Jason P's Form 4 filing
Dyne Therapeutics, Inc. (DYN) · filed Jul 8, 2026
- Accession no.
- 0001577014-26-000014
- Filed
- Jul 8, 2026, 5:35 PM ET
- Trade date
- Jul 6-7, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 10 non-derivative transactions and 0 derivative transactions. Open-market sales total $17.9M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rhodes Jason PCIK 0001577014 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | Common Stock | SSaleDisposed | −253,039 | $22.79 | −$5,766,758.81 | 4,223,448 | Indirect | |
| Jul 6, 2026 | Common Stock | SSaleDisposed | −127,182 | $22.79 | −$2,898,477.78 | 1,217,537 | Indirect | |
| Jul 6, 2026 | Common Stock | SSaleDisposed | −100,019 | $22.79 | −$2,279,433.01 | 875,912 | Indirect | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −124,379 | $23.17 | −$2,881,861.43 | 4,099,069 | Indirect | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −29,587 | $23.62 | −$698,844.94 | 4,069,482 | Indirect | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −62,543 | $23.17 | −$1,449,121.31 | 1,154,994 | Indirect | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −14,844 | $23.62 | −$350,615.28 | 1,140,150 | Indirect | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −49,193 | $23.17 | −$1,139,801.81 | 826,719 | Indirect | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −11,665 | $23.62 | −$275,527.3 | 815,054 | Indirect | |
| Jul 7, 2026 | Common Stock | SSaleDisposed | −5,000 | $23.61 | −$118,050 | 2,962 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.